BACKGROUND: Prolonged breathing of nitric oxide reduces myocardial ischemia-reperfusion injury, but the precise mechanisms responsible for the cardioprotective effects of inhaled nitric oxide are incompletely understood. METHODS: The authors investigated the fate of inhaled nitric oxide (80 parts per million) in mice and quantified the formation of nitric oxide metabolites in blood and tissues. The authors tested whether the accumulation of nitric oxide metabolites correlated with the ability of inhaled nitric oxide to protect against cardiac ischemia-reperfusion injury. RESULTS: Mice absorbed nitric oxide in a nearly linear fashion (0.19 +/- 0.02 micromol/g x h). Breathing nitric oxide rapidly increased a broad spectrum of nitric oxide metabolites. Levels of erythrocytic S-nitrosothiols, N-nitrosamines, and nitrosyl-hemes increased dramatically within 30 s of commencing nitric oxide inhalation. Marked increases of lung S-nitrosothiol and liver N-nitrosamine levels were measured, as well as elevated cardiac and brain nitric oxide metabolite levels. Breathing low oxygen concentrations potentiated the ability of inhaled nitric oxide to increase cardiac nitric oxide metabolite levels. Concentrations of each nitric oxide metabolite, except nitrate, rapidly reached a plateau and were similar after 5 and 60 min. In a murine cardiac ischemia-reperfusion injury model, breathing nitric oxide for either 5 or 60 min before reperfusion decreased myocardial infarction size as a fraction of myocardial area at risk by 31% or 32%, respectively. CONCLUSIONS: Breathing nitric oxide leads to the rapid accumulation of a variety of nitric oxide metabolites in blood and tissues, contributing to the ability of brief periods of nitric oxide inhalation to provide cardioprotection against ischemia-reperfusion injury. The nitric oxide metabolite concentrations achieved in a target tissue may be more important than the absolute amounts of nitric oxide absorbed.
BACKGROUND: Prolonged breathing of nitric oxide reduces myocardial ischemia-reperfusion injury, but the precise mechanisms responsible for the cardioprotective effects of inhaled nitric oxide are incompletely understood. METHODS: The authors investigated the fate of inhaled nitric oxide (80 parts per million) in mice and quantified the formation of nitric oxide metabolites in blood and tissues. The authors tested whether the accumulation of nitric oxide metabolites correlated with the ability of inhaled nitric oxide to protect against cardiac ischemia-reperfusion injury. RESULTS:Mice absorbed nitric oxide in a nearly linear fashion (0.19 +/- 0.02 micromol/g x h). Breathing nitric oxide rapidly increased a broad spectrum of nitric oxide metabolites. Levels of erythrocytic S-nitrosothiols, N-nitrosamines, and nitrosyl-hemes increased dramatically within 30 s of commencing nitric oxide inhalation. Marked increases of lung S-nitrosothiol and liver N-nitrosamine levels were measured, as well as elevated cardiac and brain nitric oxide metabolite levels. Breathing low oxygen concentrations potentiated the ability of inhaled nitric oxide to increase cardiac nitric oxide metabolite levels. Concentrations of each nitric oxide metabolite, except nitrate, rapidly reached a plateau and were similar after 5 and 60 min. In a murinecardiac ischemia-reperfusion injury model, breathing nitric oxide for either 5 or 60 min before reperfusion decreased myocardial infarction size as a fraction of myocardial area at risk by 31% or 32%, respectively. CONCLUSIONS: Breathing nitric oxide leads to the rapid accumulation of a variety of nitric oxide metabolites in blood and tissues, contributing to the ability of brief periods of nitric oxide inhalation to provide cardioprotection against ischemia-reperfusion injury. The nitric oxide metabolite concentrations achieved in a target tissue may be more important than the absolute amounts of nitric oxide absorbed.
Authors: A Fox-Robichaud; D Payne; S U Hasan; L Ostrovsky; T Fairhead; P Reinhardt; P Kubes Journal: J Clin Invest Date: 1998-06-01 Impact factor: 14.808
Authors: John W Elrod; James J M Greer; Nathan S Bryan; Will Langston; Jeffrey F Szot; Henock Gebregzlabher; Stefan Janssens; Martin Feelisch; David J Lefer Journal: Arterioscler Thromb Vasc Biol Date: 2006-04-27 Impact factor: 8.311
Authors: Mark R Duranski; James J M Greer; Andre Dejam; Sathya Jaganmohan; Neil Hogg; William Langston; Rakesh P Patel; Shaw-Fang Yet; Xunde Wang; Christopher G Kevil; Mark T Gladwin; David J Lefer Journal: J Clin Invest Date: 2005-04-14 Impact factor: 14.808
Authors: Ryuji Hataishi; Ana Clara Rodrigues; Tomas G Neilan; John G Morgan; Emmanuel Buys; Sruti Shiva; Rosemary Tambouret; Davinder S Jassal; Michael J Raher; Elissa Furutani; Fumito Ichinose; Mark T Gladwin; Anthony Rosenzweig; Warren M Zapol; Michael H Picard; Kenneth D Bloch; Marielle Scherrer-Crosbie Journal: Am J Physiol Heart Circ Physiol Date: 2006-01-27 Impact factor: 4.733
Authors: Shizuka Minamishima; Kotaro Kida; Kentaro Tokuda; Huifang Wang; Patrick Y Sips; Shizuko Kosugi; Joseph B Mandeville; Emmanuel S Buys; Peter Brouckaert; Philip K Liu; Christina H Liu; Kenneth D Bloch; Fumito Ichinose Journal: Circulation Date: 2011-09-19 Impact factor: 29.690
Authors: Robert T Mallet; Eugenia B Manukhina; Steven Shea Ruelas; James L Caffrey; H Fred Downey Journal: Am J Physiol Heart Circ Physiol Date: 2018-04-13 Impact factor: 4.733